Given these unique actions of seladelpar to protect liver function in the face of residual insults, future clinical trials in NASH and other liver diseases should consider combining this selective PPARδ agonist with other agents to reach the desired endpoint of preventing or delaying the need for liver transplantation. This evidence concerns the gene PPARD and metabolic dysfunction-associated steatohepatitis.